{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-077374","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.861376+00:00","generated_at":"2026-05-20T10:45:28.379672+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome settles SUNOSI patent litigation with Hetero; generic entry delayed until 2040","bullets":["Settlement resolves patent litigation with Hetero over generic version of SUNOSI (solriamfetol).","Hetero licensed to sell generic SUNOSI on or after Sept 1, 2040 (if pediatric exclusivity) or March 1, 2040.","Settlement agreement subject to review by FTC and DOJ.","Similar patent litigation against other SUNOSI generic applicants remains pending in New Jersey court."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-077374","json":"https://secwatch.observer/filing/0000950170-25-077374.json","markdown":"https://secwatch.observer/filing/0000950170-25-077374.md","text":"https://secwatch.observer/filing/0000950170-25-077374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025077374/0000950170-25-077374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025077374/axsm-20250527.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:45:28.379672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}